Literature DB >> 9678587

Alpha-glucosidase inhibitors as potential broad based anti-viral agents.

A Mehta1, N Zitzmann, P M Rudd, T M Block, R A Dwek.   

Abstract

N-Linked oligosaccharides play many roles in the fate and functions of glycoproteins. One function is to assist in the folding of proteins by mediating interactions of the lectin-like chaperone proteins calnexin and calreticulin with nascent glycoproteins. These interactions can be prevented by inhibitors of the alpha-glucosidases and this causes some proteins to be misfolded and retained within the endoplasmic reticulum. In human immunodeficiency virus (HIV) and hepatitis B virus (HBV) the misfolding of key viral envelope glycoproteins interferes with the viral life cycle. It has been demonstrated in an animal model of chronic HBV that glucosidase inhibitors can alter glycosylation and have anti-viral activity. As the mechanism of action of alpha-glucosidase inhibitors is the induction of misfolded or otherwise defective viral glycoproteins, such inhibitors may be useful therapeutics for many viruses, especially those which bud from the endoplasmic reticulum (where protein folding takes place). For example bovine viral diarrhea virus, a pestivirus akin to hepatitis C virus, is also extremely sensitive to glucosidase inhibition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678587     DOI: 10.1016/s0014-5793(98)00525-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  42 in total

1.  Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum.

Authors:  M P Courageot; M P Frenkiel; C D Dos Santos; V Deubel; P Desprès
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Characterization of different crystal forms of the alpha-glucosidase MalA from Sulfolobus solfataricus.

Authors:  Heidi Asschenfeldt Ernst; Martin Willemoës; Leila Lo Leggio; Gordon Leonard; Paul Blum; Sine Larsen
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-11-05

Review 3.  For whom the bell tolls? DING proteins in health and disease.

Authors:  Anne Berna; François Bernier; Eric Chabrière; Mikael Elias; Ken Scott; Andrew Suh
Journal:  Cell Mol Life Sci       Date:  2009-03-17       Impact factor: 9.261

4.  Antiviral effects of an iminosugar derivative on flavivirus infections.

Authors:  Shu-Fen Wu; Chyan-Jang Lee; Ching-Len Liao; Raymond A Dwek; Nicole Zitzmann; Yi-Ling Lin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Specificity of Processing α-glucosidase I is guided by the substrate conformation: crystallographic and in silico studies.

Authors:  Megan K Barker; David R Rose
Journal:  J Biol Chem       Date:  2013-03-27       Impact factor: 5.157

6.  Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.

Authors:  Ender Simsek; Anand Mehta; Tianlun Zhou; Raymond A Dwek; Timothy Block
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively.

Authors:  J M Mackenzie; E G Westaway
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Homology modeling and molecular interaction field studies of alpha-glucosidases as a guide to structure-based design of novel proposed anti-HIV inhibitors.

Authors:  C H Tomich; P da Silva; Ivone Carvalho; C A Taft
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

Review 9.  Glycosidase inhibition: assessing mimicry of the transition state.

Authors:  Tracey M Gloster; Gideon J Davies
Journal:  Org Biomol Chem       Date:  2009-11-05       Impact factor: 3.876

10.  Bortezomib inhibits hepatitis B virus replication in transgenic mice.

Authors:  Prasanthi Bandi; Mayra L Garcia; Carmen J Booth; Francis V Chisari; Michael D Robek
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.